- Chief Technology Officer
- OncologyVoiceNetwork
- Joined on Jan 12, 2024
Joseph's Feed
42 items published
Breaking Silos in Oncology Dr Ramin Farhood & Dr Kirk Shepard on Voices of Oncology
New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures
<ul> <li><em>Voices of Oncology: Fostering a Collaborative Community of Experts to Accelerate Cancer Cures</em>&nbsp;is a book by Kirk V. Shepard, M.D., and Ramin Farhood,...
Interim Impact The Rise of Fractional Medical Affairs Roles in Pharmas New Reality
<p>In this episode, Tom Caravela and Daniel Snyder explore the rise of fractional medical affairs roles in the post-COVID era. They define interim and fractional positions, highlighting how they...
From Interactions to Impact: How Medical Affairs Can Prove Its Value
<p>In this episode, Tom Caravela is joined by Lusine Kodagolian to discuss how to measure the value of medical affairs. They explore the SMART framework, emphasizing its application in measuring...
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
Visionaries Behind Oncology Voice Network: Dr. Ramin Farhood & Dr. Kirk Shepard
Introducing OncologyVoiceNetwork.com
AI-powered real-world evidence: Strategically enhancing value and access
<ul> <li>Real-world evidence (RWE) complements traditional randomized controlled trials by providing insights from diverse data sources, helping healthcare decision-makers with coverage, ...
Bringing the Patient Voice into Company-Sponsored Publications: The Med Comms Perspective
<p>Continuing our look at increasing patient participation in the scientific publication process, this episode of InformED will look at the process from a medical communications perspective. Our...
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
<ul> <li>The ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) was introduced in 2015 to standardize the assessment of clinical benefits from cancer treatments.</li> <li>E...
Association between control group therapy and magnitude of clinical benefit of cancer drugs
<ul> <li>The study investigated the impact of control group therapy on various clinical benefit scales like ASCO-VF, ESMO-MCBS, NCCN Evidence Blocks, and ASCO-CRC.</li> <li>R...
Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval
<ul> <li>Among 5 oncology indications, 26.1% of eligible treatment initiations involved an Accelerated Approval (AA) indication that was later withdrawn due to lack of benefit.</li>...
Biosimilars in Oncology: Latest Trends and Regulatory Status
<ul> <li>Biologic-based medicines are crucial in treating various diseases, particularly cancer, and hold a significant portion of the global pharmaceutical market.</li> <li>...
FDA validation of surrogate endpoints in oncology: 2005–2022
<p>ere are summary bullets based on the provided text:</p> <ul> <li>The FDA has increasingly approved oncologic drugs based on surrogate endpoints, which often lack a demonst...
Oncology biosimilars: New developments and future directions
<ul> <li><strong>Biologics</strong> are essential in cancer treatment as both therapeutic and supportive care agents, but they are expensive and require extensive testing to e...
Illuminating science for patients and healthcare professionals through plain language podcasts
<p><strong>Note this is a video recording of an online meeting conducted using the Zoom.us platform. Inevitably such recordings suffer a little in terms of their production values because ...
Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020
<ul> <li>The US has worse cancer-related outcomes compared to other high-income countries and has the highest cost of cancer care globally.</li> <li>High costs may be attribu...
Identification of Barriers Preventing Biosimiliar Oncology Medication Adoption
<ul> <li><strong>Biosimilars</strong> are biologic medical products that are almost identical to original biologics but are produced by different companies. They are safe, eff...
Research Highlights In The News From ESMO
<div> <div dir="auto" data-message-id="542f77d5-2355-414a-94b7-35def0e85761" data-message-author-role="assistant"> <div> <div> <ul> <...
Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020
<ul> <li>The study evaluates the overall survival (OS) benefit of cancer drugs approved in China between 2005 and 2020.</li> <li>Out of 141 cancer drug indications approved, ...
How do cancer clinicians perceive real-world data and the evidence derived therefrom? Findings from an international survey of the European Organisation for Research and Treatment of Cancer
<ul> <li>Real-world evidence (RWE) is increasingly being used in the development and decision-making processes for anticancer therapies, but clinician views on its use are unclear.</li...
Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration
<ul> <li>The study examines the eligibility for individual participant data (IPD) sharing from clinical trials that supported the FDA approval of anticancer medicines over the past 10 yea...
Uptake of Oncology Biosimilars: Managed Care Strategies to Improve Value-Based Care Systems
<ul> <li>Biosimilars offer a cost-effective alternative in oncology, expanding access to cancer care, but their utilization is inconsistent due to varying perceptions and knowledge among ...
A Comprehensive Comparison of Additional Benefit Assessment Methods Applied by Institute for Quality and Efficiency in Health Care and European Society for Medical Oncology for Time-to-Event Endpoints After Significant Phase III Trials—A Simulation Study
<ul> <li>The European Society for Medical Oncology (ESMO) and the German Institute for Quality and Efficiency in Health Care (IQWiG) use different methods for assessing additional benefit...
Clinical benefit of cancer drugs approved in Switzerland 2010–2019
<ul> <li>The study evaluates the clinical benefit of cancer drugs approved in Switzerland between 2010 and 2019 using three different frameworks: ESMO-MCBS, ASCO-VF, and OLUtool.</li&g...
Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022
<ul> <li><strong>Importance:</strong> Evaluating the cost-effectiveness of adjuvant therapies based on the cost per event averted.</li> <li><strong>Objectiv...
Towards a novel approach guiding the decision-making process for anticancer treatment in patients with advanced cancer: framework for systemic anticancer treatment with palliative intent
<ul> <li>Patient-centered decisions in advanced cancer care demand a step-wise decisional process, not a single decision act.<br><br></li> <li>The decision proces...
Recent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approval
<ul> <li>The study examines the impact of drugs approved through the FDA&rsquo;s accelerated approval program on state Medicaid spending.</li> <li>From 1992 to 2020, 216 ...
Coronavirus (COVID-19): Its Impact on Publication Planning (04/29/2020)
<p data-role="course-item-description">The Coronavirus (COVID-19) pandemic has impacted nearly every facet of our personal and professional lives. Medical publication professionals are...
The FDA Oncology Center of Excellence and Precision Medicine
<p>The FDA is exploring real-world evidence to enhance understanding of the long-term safety and efficacy of oncology drugs. Initiatives like the Information Exchange and Data Transformation ini...